Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment

International Journal of Laboratory Hematology

Volumn 30, Issue 1, 2008, Pages 17-25

  Passam, F H ^a,e   Sfiridaki, A ^b   Pappa, C ^c   Kyriakou, D ^d   Petreli, E ^a   Roussou, P A ^a   Alexandrakis, M G ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b Venizelion General Hospital   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Interleukin 16; Interleukin 2; Interleukin 8; Non Hodgkin lymphoma; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOKINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; INTERLEUKIN 16; INTERLEUKIN 2; INTERLEUKIN 8; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VASCULOTROPIN; VINCRISTINE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKINS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REMISSION INDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38049036969     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2006.00890.x     Document Type: Article

References (66)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine 329, 987 994.
2. Adams S.A. Subramanian V. (1999) The angiogenins: an emerging family of ribonuclease related proteins with diverse cellular functions. Angiogenesis 3, 189 199.
3. Alexandrakis M.G., Passam F.H., Kyriakou D.S., Christophoridou A.V., Perisinakis K., Hatzivasili A., Foudoulakis A. Castanas E. (2004) Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity. American Journal of Hematology 75, 101 106.
4. Alexandrakis M.G., Passam F.H., Sfiridaki A., Kyriakou D.S., Petreli E. Roussou P. (2003) Elevated serum angiogenin in multiple myeloma. Hematology Journal 4, 454 455.
5. Aref S., Mabed M., Zalata K., Sakrana M. El Askalany H. (2004) The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome. Leukemia Lymphoma 45, 499 506.
6. Arias V. Soares F.A. (2000) Vascular density (tumor angiogenesis) in non-Hodgkin's lymphomas and florid follicular hyperplasia: a morphometric study. Leukemia Lymphoma 40, 157 166.
7. Asadullah K., Haeussler-Quade A., Gellrich S., Hanneken S., Hansen-Hagge T.E., Docke W.D., Volk H.D. Sterry W. (2000) IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Experimental Dermatology 9, 248 251.
8. Baggiolini M., Walz A. Kunkel S.L. (1989) Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. Journal of Clinical Investigation 84, 1045 1049.
9. Bairey O., Zimra Y., Kaganovsky E., Shaklai M., Okon E. Rabizadeh E. (2000) Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Medical Oncology 17, 314 318.
10. Bertolini F., Fusetti L., Mancuso P., Gobbi A., Corsini C., Ferrucci P.F., Martinelli G. Pruneri G. (2000) Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 96, 282 287.
11. Bertolini F., Paolucci M., Peccatori F., Cinieri S., Agazzi A., Ferrucci P.F., Cocorocchio E., Goldhirsch A. Martinelli G. (1999) Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. British Journal of Haematology 106, 504 509.
12. + cell-specific chemoattractant interleukin-16 in mycosis fungoides. Journal of Investigative Dermatology 113, 658 663.
13. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., Lister T.A., Vose J., Grillo-Lopez A., Hagenbeek A., Cabanillas F., Klippensten D., Hiddemann W., Castellino R., Harris N.L., Armitage J.O., Carter W., Hoppe R. Canellos G.P. (1999) Report of an international workshop to standardize response critera for non Hodgkin's lymphoma. Journal of Clinical Oncology 17, 1244 1253.
14. Cohen T., Nahari D., Cerem L.W., Neufeld G. Levi B.Z. (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. Journal of Biological Chemistry 271, 736 741.
15. Cozzolino F., Torcia M., Lucibello M., Morbidelli L., Ziche M., Platt J., Fabiani S., Brett J. Stern D. (1993) Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. Journal of Clinical Investigation 91, 2504 2512.
16. Crivellato E., Nico B., Vacca A. Ribatti D. (2003) B-cell non-Hodgkin's lymphomas express heterogenous patterns of neovascularization. Haematologica 88, 671 678.
17. Cruikshank W.W., Kornfeld H. Center D.M. (2000) Interleukin-16. Journal of Leukocyte Biology 67, 757 766.
18. Durrant I.J., Prentice H.G. Richards S.M. (1997) Intensification of treatment for adults with acute lumphoblastic leukemia: results of the U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults. British Journal of Haematology 99, 84 92.
19. el-Far M., Fouda M., Yahya R. el-Baz H. (2004) Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. Journal of Physiology and Biochemistry 60, 253 258.
20. Faderl S., Do K.A., Johnson M.M., Keating M., O'brien S., Jilani I., Ferrajoli A., Ravandi-Kashani F., Aguilar C., Dey A., Thomas D.A., Giles F.J., Kantarjian H.M. Albitar M. (2005) Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood 106, 4303 4307.
21. Folkman J. (1971) Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 285, 1182 1186.
22. Foss H.D., Araujo I., Demel G., Klotzbach H., Hummel M. Stein H. (1997) Expression of vascular endothelial growth factor in lymphomas and Castleman disease. Journal of Pathology 183, 44 50.
23. Ganjoo K.N., Gordon L., Robertson M.J. Horning S.J. (2004) Rituximab, bevacizumab (Avastin) and CHOP (RA-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL). ASH Annual Meeting Abstracts. Blood 104, 1384.
24. Giles F., Vose J., Do K., Johnson M., Manshouri T., Bociek G., Bierman P., O'Brien S., Kantarjian H., Armitage J. Albitar M. (2004) Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leukemia Research 28, 595 604.
25. Hazar B., Paydas S., Zorludemir S., Sahin B. Tuncer I. (2003) Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leukemia Lymphoma 44, 2089 2093.
26. Ho C.L., Sheu L.F. Li C.Y. (2002) Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Applied Immunohistochemistry and Molecular Morphology 10, 316 321.
27. Huang S.P., Wu M.S., Shun C.T., Wang H.P., Lin M.T., Kuo M.L. Lin J.T. (2004) Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. Journal of Biomedical Science 11, 517 527.
28. Kadowaki I., Ichinohasama R., Harigae H., Ishizawa K., Okitsu Y., Kameoka J. Sasaki T. (2005) Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. British Journal of Haematology 130, 869 877.
29. Kantarjian H.M., O'Brien S., Smith T.L., Cortes J., Giles F.J., Beran M., Pierce S., Huh Y., Andreeff M., Koller C., Ha C.S., Keating M.J., Murphy S. Freireich E.J. (2000) Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. Journal of Clinical Oncology 18, 547 561.
30. Koike M., Sekigawa I., Okada M., Matsumoto M., Iida N., Hashimoto H. Oshimi K. (2002) Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leukemia Research 26, 705 711.
31. Koster A., van Krieken J.H., Mackenzie M.A., Schraders M., Borm G.F., van der Laak J.A., Leenders W., Hebeda K. Raemaekers J.M. (2005) Increased vascularization predicts favorable outcome in follicular lymphoma. Clinical Cancer Research 11, 154 161.
32. Kovacs E. (2001) The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomedicine & Pharmacotherapy 55, 111 116.
33. Li A., Varney M.L., Valasek J., Godfrey M., Dave B.J. Singh R.K. (2005) Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 8, 63 71.
34. Ma A., Koka R. Burkett P. (2006) Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annual Review of Immunology 24, 657 679.
35. Manghi M. (2000) Angiogenesis and angiogenic mediators in hematological malignancies. British Journal of Haematology 111, 43 51.
36. McClintock J.Y. Wagner E.M. (2005) Role of IL-6 in systemic angiogenesis of the lung. Journal of Applied Physiology 99, 861 866.
37. Miyake H., Hara I., Yamanaka K., Gohji K., Arakawa S. Kamidono S. (1999) Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer 86, 316 324.
38. Molica S., Vitelli G., Levato D., Giannarelli D., Vacca A., Cuneo A., Ribatti D. Digiesi G. (2004) Serum angiogenin is not elevated in patients with early B-cell chronic lymphocytic leukemia but is a prognostic factor for disease progression. European Journal of Haematology 73, 36 42.
39. Moore B.B., Arenberg D.A., Addison C.L., Keane M.P. Strieter R.M. (1998) Tumor angiogenesis is regulated by CXC chemokines. Journal of Laboratory and Clinical Medicine 132, 97 103.
40. Mor F., Quintana F.J. Cohen I.R. (2004) Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. Journal of Immunology 172, 4618 4623.
41. Niitsu N., Okamoto M., Nakamine H., Yoshino T., Tamaru J., Nakamura S., Higashihara M. Hirano M. (2002) Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma. European Journal of Haematology 68, 91 100.
42. Nilsson M.B., Langley R.R. Fidler I.J. (2005) Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Research 65, 10794 10800.
43. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T. Carbone P.P. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 5, 649 655.
44. Ozdemir F., Aydin F., Yilmaz M., Kavgaci H., Bektas O., Yavuz M.N. Yavuz A.A. (2004) The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive non-Hodgkin's lymphoma (NHL). Journal of Experimental and Clinical Cancer Research 23, 485 488.
45. Panteli K.E., Hatzimichael E.C., Bouranta P.K., Katsaraki A., Seferiadis K., Stebbing J. Bourantas K.L. (2005) Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. British Journal of Haematology 130, 709 715.
46. Passalidou E., Stewart M., Trivella M., Steers G., Pillai G., Dogan A., Leigh I., Hatton C., Harris A., Gatter K. Pessella F. (2003) Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma. British Journal of Cancer 88, 553 559.
47. Pazgal I., Zimra Y., Tzabar C., Okon E., Rabizadeh E., Shaklai M. Bairey O. (2002) Expression of basic fibroblast growth factor is associated with a poor outcome in non-Hodgkin's lymphoma. British Journal of Cancer 86, 1770 1775.
48. Pedersen L.M., Jurgensen G.W. Johnsen H.E. (2005a) Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma. British Journal of Haematology 128, 813 819.
49. Pedersen L.M., Klausen T.W., Davidsen U.H. Johnsen H.E. (2005b) Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Annals of Hematology 84, 510 516.
50. Retzlaff S., Padro T., Koch P., Oelmann E., Lugering N., Mesters R.M. Berdel W.E. (2002) Interleukin 8 and Flt3 ligand as markers of advanced disease in primary gastrointestinal non-Hodgkin's lymphoma. Oncology Reports 9, 525 527.
51. Ribatti D., Vacca A., Nico B., Fanelli M., Roncali L. Dammacco F. (1996) Angiogenesis spectrum in the stroma of B-cell non Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. European Journal of Haematology 56, 45 53.
52. Sakkoula E., Pipili-Synetos E. Maragoudakis M.E. (1997) Involvement of nitric oxide in the inhibition of angiogenesis by interleukin-2. British Journal of Pharmacology 122, 793 795.
53. Salven P., Orpana A., Teerenhovi L. Joensuu H. (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96, 3712 3718.
54. Salven P., Teerenhovi L. Joensuu H. (1999) A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 94, 3334 3339.
55. Salven P. (2001) Angiogenesis in lymphoproliferative disorders. Acta Haematologica 106, 184 189.
56. Sharma V., Sparks J.L. Vail J.D. (2000) Human B-cell lines constitutively express and secrete interleukin-16. Immunology 99, 266 271.
57. Shimoyama S. Kaminishi M. (2003) Angiogenin in sera as an independent prognostic factor in gastric cancer. Journal of Cancer Research and Clinical Oncology 129, 239 244.
58. Shimoyama S., Shimizu N., Tsuji E., Yamasaki K., Kawahara M. Kaminishi M. (2002) Distribution of angiogenin and its gene message in colorectal cancer patients and their clinical relevance. Anticancer Research 22, 1045 1052.
59. Smolej L., Andrys C., Maisnar V., Pour L. Maly J. (2005) Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta Medica (Hradec Kralove) 48, 57 58.
60. Srivastava M.D., Sivastava R. Srivastava B.I. (1993) Constitutive production of interleukin-8 (IL-8) by normal and malignant human B-cells and other cell types. Leukemia Research 17, 1063 1069.
61. Stasi R., Conforti M., Del Poeta G., Simone M.D., Coppetelli U., Tribalto M., Cantonetti M., Perrotti A., Venditti A. Papa G. (1992) Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas. Haematologica 77, 518 521.
62. Stasi R., Zinzani L., Galieni P., Lauta V.M., Damasio E., Dispensa E., Dammacco F., Venditti A., Del Poeta G., Cantonetti M., Perrotti A., Papa G. Tura S. (1995) Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma. European Journal of Haematology 54, 9 17.
63. Vacca A., Ribatti D., Ruco L., Giacchetta F., Nico B., Quondamatteo F., Ria R., Iurlaro M. Dammacco F. (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. British Journal of Cancer 79, 965 970.
64. Verstovsek S., Kantarjian H., Aguayo A., Manshouri T., Freireich E., Keating M., Estey E. Albitar M. (2001) Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. British Journal of Haematology 114, 290 295.
65. Yuan A., Chen J.J., Yao P.L. Yang P.C. (2005) The role of interleukin-8 in cancer cells and microenvironment interaction. Frontiers in Bioscience 10, 853 865.
66. Zhao W.L., Mourah S., Mounier N., Leboeuf C., Daneshpouy M.E., Legres L., Meignin V., Oksenhendler E., Maignin C.L., Calvo F., Briere J., Gisselbrecht C. Janin A. (2004) Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Laboratory Investigation 84, 1512 1519.